CelLBxHealth Executives and ESOT Boost Holdings After Oversubscribed Placing

The latest announcement is out from ANGLE plc ( (GB:CLBX) ).

CelLBxHealth plc has disclosed significant share purchases by its top executives following last month’s oversubscribed placing, with Executive Chairman Jan Groen and CEO Peter Collins each acquiring 5 million shares and Finance Director Sinéad Armstrong buying 2.5 million shares at 1.0 pence, resulting in respective holdings of about 0.4% and 0.2% of the enlarged share capital. In a parallel move to underpin long-term employee incentives and remuneration schemes, the company’s Employee Share Ownership Trust, managed by Zedra Trust Company, bought 2,886,742 shares at 1.1 pence, taking the trust’s holding to 3 million shares, or 0.3% of issued capital, leaving total voting rights at 1,136,402,658 and signalling internal confidence and a stronger alignment between management, staff and shareholders.

The most recent analyst rating on (GB:CLBX) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.

Spark’s Take on GB:CLBX Stock

According to Spark, TipRanks’ AI Analyst, GB:CLBX is a Neutral.

The overall stock score reflects significant financial challenges and bearish technical indicators, which are the most impactful factors. While recent corporate events and earnings call achievements provide some positive outlook, the financial and valuation concerns weigh heavily on the score.

To see Spark’s full report on GB:CLBX stock, click here.

More about ANGLE plc

CelLBxHealth plc is a precision circulating tumour cell (CTC) intelligence company that develops innovative CTC solutions for research, drug development and clinical oncology. Its patent-protected Parsortix platform is used to harvest CTCs from blood and can be integrated with existing laboratory systems for downstream analysis, including imaging, proteomics and genomics. The business model spans product sales of Parsortix instruments and consumables, laboratory services for clinical trial support and assay development, and lab-developed tests delivered from its GCLP-certified UK laboratory, with a focus on CROs, clinical labs and strategic partnerships.

Average Trading Volume: 2,908,525

Technical Sentiment Signal: Sell

Current Market Cap: £3.65M

See more insights into CLBX stock on TipRanks’ Stock Analysis page.